Ocular Therapeut (OCUL) Stock Price, Quote & News

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 357 4000

Website: www.ocutx.com

Address:

15 Crosby Drive, Bedford, United States

MaxKlim Jun. 24 at 8:39 PM

$OCUL https://x.com/zipjet/status/2069869138730742260?s=46

0 · Reply

rizzato Jun. 24 at 7:49 PM

$OCUL let's leave me to understand Tmoney. you are saying that both company ocul and eypt will not have a green future and they are kidding us, means that big investors that own around the 90% of the shares and the great management of both company doesn't understand anything can I tell you that that sound really strange? is not easier to say again I'm totally short and trying to push the share price down to make money who are you the genius inside the lamp?????????

2 · Reply

nicky7 Jun. 24 at 7:30 PM

$OCUL 40 incoming

0 · Reply

Tmoney85285 Jun. 24 at 7:28 PM

$OCUL big time ouch. still time to short before Ollin takes over.

0 · Reply

moneybagged Jun. 24 at 6:40 PM

$OCUL Did not expect such shorting!!! I have my orders in👌😎

0 · Reply

Tmoney85285 Jun. 24 at 5:37 PM

$OCUL nice group of bulls you got here- moronic and transphobic. guy is obsessed with calling people trans. pretty telling if you ask me.

1 · Reply

Tmoney85285 Jun. 24 at 5:05 PM

$OCUL thanks for the laugh. yeah, $35 incoming when it couldn't crack (checks notes) $10.50. might wanna call pravin and ask him how those FDA talks are going now that Ollin is clearly superior and is ACTUALLY a game changing drug. tough pill for yall to swallow, market gets it though! little nicky should go back to eating popeyes and saving new york from the devil, because he's clearly losing it. LOL

1 · Reply

Tmoney85285 Jun. 24 at 5:03 PM

$OCUL hey siri, post the 6M chart for JJ to see. anyone can manipulate a chart to make a point, you dont even need a jaguar to do so!

2 · Reply

nicky7 Jun. 24 at 4:43 PM

$OCUL 35 incoming

0 · Reply

SmokenTuna Jun. 24 at 3:42 PM

$OCUL 1000 more for me! Let’s rock!

0 · Reply

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-06-18T15:20:29.000Z - 6 days ago

Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright

2026-06-18T10:31:11.000Z - 6 days ago

Ocular Therapeutix price target raised to $30 from $24 at Baird

Jun 17, 2026, 2:00 PM EDT - 7 days ago

Ocular Therapeutix Transcript: Investor Day 2026

Jun 17, 2026, 2:00 PM EDT - 7 days ago

Ocular Therapeutix Press release: FY 2026

Jun 17, 2026, 2:00 PM EDT - 7 days ago

Ocular Therapeutix Slides: FY 2026

2026-06-17T13:15:09.000Z - 7 days ago

Ocular Therapeutix trading resumes

2026-06-17T12:56:42.000Z - 7 days ago

Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA

2026-06-17T12:56:01.000Z - 7 days ago

Ocular Therapeutix to resume trading at 9:15 am ET

Jun 17, 2026, 8:45 AM EDT - 7 days ago

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

2026-06-17T12:40:11.000Z - 7 days ago

Ocular Therapeutix trading halted, news pending

Jun 10, 2026, 8:30 AM EDT - 14 days ago

Ocular Therapeutix Transcript: AGM 2026

Jun 4, 2026, 7:00 AM EDT - 20 days ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

Jun 2, 2026, 7:00 AM EDT - 22 days ago

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

May 26, 2026, 2:30 PM EDT - 4 weeks ago

Ocular Therapeutix Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 12, 2026, 6:40 PM EDT - 6 weeks ago

Ocular Therapeutix Transcript: Bank of America Global Healthcare Conference 2026

May 5, 2026, 8:00 AM EDT - 7 weeks ago

Ocular Therapeutix Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 7 weeks ago

Ocular Therapeutix Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 7 weeks ago

Ocular Therapeutix Quarterly report: Q1 2026

2026-05-05T11:59:32.000Z - 7 weeks ago

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

May 5, 2026, 7:00 AM EDT - 7 weeks ago

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Ocular Therapeutix Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 7 weeks ago

Ocular Therapeutix Proxy statement: Proxy filing

2026-04-29T13:00:19.000Z - 2 months ago

Ocular Therapeutix enrolls first patient in Axpali trial

Apr 29, 2026, 7:00 AM EDT - 2 months ago

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Apr 28, 2026, 7:00 AM EDT - 2 months ago

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Apr 27, 2026, 2:30 PM EDT - 2 months ago

Ocular Therapeutix Transcript: HCW @ Home

2026-04-13T11:22:45.000Z - 2 months ago

Ocular Therapeutix reports additional Axpaxli trial data

Apr 13, 2026, 7:00 AM EDT - 2 months ago

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Apr 1, 2026, 7:00 AM EDT - 3 months ago

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

Mar 25, 2026, 9:30 AM EDT - 3 months ago

Ocular Therapeutix Transcript: RBC Capital Markets Virtual Ophthalmology Conference

Mar 20, 2026, 5:24 PM EDT - 3 months ago

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

EYPT

Mar 11, 2026, 9:00 AM EDT - 3 months ago

Ocular Therapeutix Transcript: The Citizens Life Sciences Conference 2026

2026-03-03T11:45:13.000Z - 4 months ago

Ocular Therapeutix price target raised to $27 from $24 at BofA

2026-03-02T21:05:53.000Z - 4 months ago

Ocular Therapeutix price target raised to $28 from $21 at Clear Street

Mar 2, 2026, 9:10 AM EST - 4 months ago

Ocular Therapeutix Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:30 AM EST - 4 months ago

Ocular Therapeutix Transcript: Study update

Feb 19, 2026, 10:41 AM EST - 4 months ago

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-02-17T19:15:34.000Z - 4 months ago

Ocular Therapeutix selloff brings attractive entry point, says Citizens

2026-02-17T15:55:17.000Z - 4 months ago

Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff

Feb 17, 2026, 8:00 AM EST - 4 months ago

Ocular Therapeutix Transcript: Study result

Feb 17, 2026, 8:00 AM EST - 4 months ago

Ocular Therapeutix Press release: Study result

2026-02-17T12:17:53.000Z - 4 months ago

Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint

Feb 17, 2026, 7:08 AM EST - 4 months ago

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

REGN

Feb 13, 2026, 5:00 PM EST - 4 months ago

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Feb 6, 2026, 4:01 PM EST - 4 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-02-05T12:05:13.000Z - 4 months ago

Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)

Feb 5, 2026, 7:00 AM EST - 4 months ago

Ocular Therapeutix Annual report: Q4 2025

Feb 5, 2026, 7:00 AM EST - 4 months ago

Ocular Therapeutix Earnings release: Q4 2025

2026-01-21T12:05:23.000Z - 5 months ago

Ocular Therapeutix appoints Robinson as Global Chief Commercial Officer

MRK

2026-01-15T16:06:19.000Z - 5 months ago

Sanofi prepping higher bid for Ocular Therapeutix, IBD reports

SNY

2026-01-15T15:06:31.000Z - 5 months ago

Ocular Therapeutix rises 11.7%

Dec 3, 2025, 8:30 AM EST - 7 months ago

Ocular Therapeutix Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 9:30 AM EST - 7 months ago

Ocular Therapeutix Transcript: Jefferies London Healthcare Conference 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Ocular Therapeutix Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Ocular Therapeutix Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Ocular Therapeutix Earnings release: Q3 2025

Nov 4, 2025, 7:05 AM EST - 8 months ago

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 7:00 AM EST - 8 months ago

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Oct 7, 2025, 7:00 AM EDT - 9 months ago

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Sep 30, 2025, 2:00 PM EDT - 9 months ago

Ocular Therapeutix Transcript: Investor Day 2025

Sep 30, 2025, 2:00 PM EDT - 9 months ago

Ocular Therapeutix Press release: FY 2025

Sep 30, 2025, 2:00 PM EDT - 9 months ago

Ocular Therapeutix Slides: FY 2025

Sep 30, 2025, 7:08 AM EDT - 9 months ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Sep 30, 2025, 6:21 AM EDT - 9 months ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Sep 9, 2025, 12:50 PM EDT - 10 months ago

Ocular Therapeutix Transcript: Baird Global Healthcare Conference 2025

Sep 8, 2025, 2:35 PM EDT - 10 months ago

Ocular Therapeutix Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 13, 2025, 2:00 PM EDT - 11 months ago

Ocular Therapeutix Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Ocular Therapeutix Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Ocular Therapeutix Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

Ocular Therapeutix Earnings release: Q2 2025

Jun 26, 2025, 1:54 PM EDT - 1 year ago

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Jun 16, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

May 27, 2025, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 20, 2025, 4:30 PM EDT - 1 year ago

Ocular Therapeutix Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 2:35 PM EDT - 1 year ago

Ocular Therapeutix Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

May 13, 2025, 12:20 PM EDT - 1 year ago

Ocular Therapeutix Transcript: Bank of America 2025 Healthcare Conference

May 7, 2025, 9:00 AM EDT - 1 year ago

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Quarterly report: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings release: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 7, 2025, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Mar 27, 2025, 7:00 PM EDT - 1 year ago

Ocular Therapeutix Slides: Corporate Presentation

Mar 10, 2025, 10:00 AM EDT - 1 year ago

Ocular Therapeutix Transcript: Leerink Global Healthcare Conference 2025

Mar 4, 2025, 11:50 AM EST - 1 year ago

Ocular Therapeutix Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Annual report: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings release: Q4 2024

Feb 24, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Feb 3, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Jan 14, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Jan 13, 2025, 8:15 PM EST - 1 year ago

Ocular Therapeutix Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 10, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 1:30 PM EST - 1 year ago

Ocular Therapeutix Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Nov 26, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings release: Q3 2024

Nov 13, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Nov 6, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Oct 2, 2024, 3:00 PM EDT - 1 year ago

Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Ocular Therapeutix Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at September Retina Meetings

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Earnings Call Transcript: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Quarterly report: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Earnings release: Q2 2024

Aug 7, 2024, 7:10 AM EDT - 2 years ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Jul 31, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Jul 10, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Jun 13, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Jun 13, 2024, 2:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: Investor Day 2024

Jun 13, 2024, 2:00 PM EDT - 2 years ago

Ocular Therapeutix Slides: FY 2024

Jun 5, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 4, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2024, 6:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: BofA Securities 2024 Health Care Conference

May 13, 2024, 1:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: The Citizens JMP Life Sciences Conference

May 7, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

May 7, 2024, 4:00 PM EDT - 2 years ago

Ocular Therapeutix Quarterly report: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Ocular Therapeutix Earnings release: Q1 2024

May 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Proxy statement: Proxy Filing

May 6, 2024, 8:16 PM EDT - 2 years ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

May 3, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

May 1, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Proxy statement: Proxy Filing

Apr 18, 2024, 7:00 AM EDT - 2 years ago

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

MaxKlim Jun. 24 at 8:39 PM

$OCUL https://x.com/zipjet/status/2069869138730742260?s=46

0 · Reply

rizzato Jun. 24 at 7:49 PM

2 · Reply

nicky7 Jun. 24 at 7:30 PM

$OCUL 40 incoming

0 · Reply

Tmoney85285 Jun. 24 at 7:28 PM

$OCUL big time ouch. still time to short before Ollin takes over.

0 · Reply

moneybagged Jun. 24 at 6:40 PM

$OCUL Did not expect such shorting!!! I have my orders in👌😎

0 · Reply

Tmoney85285 Jun. 24 at 5:37 PM

$OCUL nice group of bulls you got here- moronic and transphobic. guy is obsessed with calling people trans. pretty telling if you ask me.

1 · Reply

Tmoney85285 Jun. 24 at 5:05 PM

1 · Reply

Tmoney85285 Jun. 24 at 5:03 PM

$OCUL hey siri, post the 6M chart for JJ to see. anyone can manipulate a chart to make a point, you dont even need a jaguar to do so!

2 · Reply

nicky7 Jun. 24 at 4:43 PM

$OCUL 35 incoming

0 · Reply

SmokenTuna Jun. 24 at 3:42 PM

$OCUL 1000 more for me! Let’s rock!

0 · Reply

Twitgb Jun. 24 at 3:17 PM

$OCUL when things dont go well and ghouls start to crawl out, you can be sure it will turn for the better. Always pestering when the tides turn. You will see, hppened on other boards. Lets go up 30% and they will find another board to piss.

1 · Reply

Tmoney85285 Jun. 24 at 3:13 PM

$OCUL y'all had your chance to get out in the mid 10's. you would've looked dare i say, smart? shorts own this one- and if you're looking to $EYPT to save you, that's equally as pathetic.

0 · Reply

TickrTalk0007 Jun. 24 at 3:08 PM

$OCUL pharma has way too many options to buy from... Axpaxli is not the one.

1 · Reply

Tmoney85285 Jun. 24 at 2:52 PM

$OCUL little buddy and his sidekick are so upset today. maybe they should invest in Wendy's LMAO

1 · Reply

Twitgb Jun. 24 at 2:37 PM

$VKTX $OCUL Here is the fortuneteller, with his imaginary friends. He is always right, right? :D

1 · Reply

KimboIce Jun. 24 at 2:24 PM

$OCUL $EYPT you are at break even . Quit while you can . There are far less risky shorts out there . If EYPT Lugano results are positive, I can see Ocul go up 30-50% on the news. MM’s are long-term strategic thinkers . They are not nubes tracking the daily . The market sees two companies = 2X resources fasts tracks new SOC . It’s ironic that management teams hate each other and need each other at the same time .

1 · Reply

rizzato Jun. 24 at 2:15 PM

$OCUL Wellcome back DROPPPPPPPPPPPPPPPPPPPP

0 · Reply

TickrTalk0007 Jun. 24 at 2:05 PM

$OCUL great defense by bulls... this is going to sting

1 · Reply

Tmoney85285 Jun. 24 at 2:03 PM

$OCUL LMAO- $XBI hits $150 and this is going back to the $9's. such easy money, glad i'm not a sheep/moron

0 · Reply

Tmoney85285 Jun. 24 at 1:54 PM

$OCUL yeah big pharma simply doesn't care. no one wants to be caught buying Iveric #2. sell for $11, it's still a rip off for whoever acquires it. no one, and i mean no one, is interested in buying this.

0 · Reply

Tmoney85285 Jun. 24 at 1:52 PM

$OCUL another successful bagholder! congrats!

0 · Reply

Tmoney85285 Jun. 24 at 1:51 PM

$OCUL bad news for the cult this morning. yikes.

0 · Reply

Market Cap	2.21B
Revenue (ttm)	51.95M
Net Income (ttm)	-265.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-511.92%
Debt to Equity Ratio	0.12

Volume	2,764,700
Avg Vol	2,931,226
Day's Range	N/A - N/A
Shares Out	218.96M
Stochastic %K	63%
Beta	0.89
Analysts	Strong Sell
Price Target	$27.10